DIFICLIR™ is a macrocyclic anti-bacterial agent, formulated as film-coated tablets and granules for oral suspension. The tablets are indicated for the treatment of Clostridioides difficile infections (CDI) in adult and paediatric patients with a body weight of at least 12.5 kg. The granules are indicated in CDI in adults and paediatric patients from birth to < 18 years of age.
DIFICLIR™ tablets and granules are registered in 32 and 31 countries in Europe, Middle East and Africa respectively. DIFICLIR™ is available as film coated tablets and has gained approval of granules for oral suspension.
Last update: January 2021.
All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Asacol™, Octasa™, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep™, Entocort™, Entocir™, Entocord™, Budecol™ and DIFICLIR™ are either registered or applied for in up to 70 countries. The rights to Entocort, including the rights to the trademark, are owned by Tillotts in various countries (transfer of market authorisations to Tillotts in process) except for the USA.
Product information on this website is limited, with the aim of providing a summary for general information purposes for a wide audience regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.